Wavelength Pharmaceuticals has significantly expanded production of APIs for certain pharmaceuticals being used to manage respiratory critical care patients as a result of the coronavirus pandemic. Products in demand include Midazolam, Cisatracurium, and Rocuronium.

Wavelength also recently launched new API CDMO (contract development and manufacturing) services that leverage the company’s expertise in complex chemistry, crystalline forms, and particle design for development and manufacturing of new APIs. The company provides a range of production needs, from preclinical grams to multi-ton commercial quantities, at the required quality, with complete regulatory support, with the goal of simplifying and de-risking its supply chain.

Iftach Seri, CEO of Wavelength Pharmaceuticals said, “Our robust supply chain and impeccable regulatory track record are enabling us to quickly respond to the urgent need for life-saving care for critically ill COVID-19 patients. We are proud of our highly experienced team, who is working tirelessly to treble and quadruple our production and supply of these essential APIs for patients in the U.S. and Europe.” 

Mr. Seri added, “Our commitment to being ‘always aligned’ with the needs of our customers drove us to invest in the required capabilities and expertise that now allow us to respond so quickly to the urgent need for respiratory critical care drugs for COVID-19 patients. It also underlies our decision to share our extensive experience with customers and collaborators via our CDMO service unit. We are honored to be able to offer these products and services to support customers and patients during these challenging times.”